An anti-SARS-CoV-2 polyclonal hyperimmune globulin (H-IG) is being developed by the company to treat infected, high-risk individuals. Takeda Pharmaceutical Company Ltd. has said it will…
Read More Takeda Pharmaceuticals Initiates Plasma-Derived Therapy for COVID-19